ArticleHeart rhythm O22025
Glutathione peroxidase 4 as a potential biomarker for atrial fibrosis and recurrence of atrial fibrillation.
Article in Heart rhythm O2, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- FTO-mediated GPX4 m6A modification in ferroptosis-induced DNA damage and inflammatory response during acute lung injury.Journal of bioenergetics and biomembranes · 2026Article
- The Influence of Basic Therapy and New Drugs on NO-Dependent Mechanisms of Cardiac Destruction in Chronic Heart Failure.Biomedicines · 2026Review
- Impact of gut microbiome on atrial fibrillation: Mechanistic insights and future directions in individualized medicine.World journal of cardiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrosis mediates the development and maintenance of atrial fibrillation (AF). Glutathione peroxidase 4 (GPX4) is a ferroptosis biomarker. Little is known about ferroptosis in AF or the relationship between GPX4 and atrial fibrosis. Objective: This study aimed to evaluate the predictive value of GPX4 for AF recurrence after ablation and the relationship between atrial fibrosis and ferroptosis. Methods: This study included 249 patients with AF who underwent ablation. The levels of serum GPX4 and transforming growth factor β (TGFβ) were evaluated by enzyme-linked immunosorbent assay. The primary outcome was AF recurrence during 12 months of follow-up. Results: According to the tertiles of TGFβ, 249 patients were divided into 3 groups. With the increase of TGFβ, the serum level of GPX4 was decreased. After 12 months of follow-up, 54 patients experienced recurrence of AF. Multivariate Cox regression analysis revealed that the GPX4 level was an independent predictor of F recurrence (hazard ratio 0.308). After adjusting for potential confounding factors, the tertiles of GPX4 remained predictors of AF recurrence. Correlation analysis indicated that GPX4 was associated with atrial fibrosis and left atrial size. Receiver-operating characteristic analysis showed that the cutoff value for AF recurrence was 3740 pg/mL. Furthermore, incorporating GPX4 into the left atrial dimensional index and TGFβ model significantly improved the prediction of recurrent AF risk. Conclusion: GPX4 showed excellent predictive value for AF recurrence and is negatively correlated with TGFβ, indicating that ferroptosis may be involved in atrial fibrosis. This model can serve as a reference for clinical decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.